Rhabdomyosarcoma

Overview - Malignant Muscle Mayhem

• Most common soft tissue sarcoma in children, arising from primitive mesenchymal cells (rhabdomyoblasts).
• Bimodal age distribution: peaks at 2-6 years and 15-19 years.
• Common Sites:
  • Head & Neck (esp. orbit, parameningeal)
  • Genitourinary (bladder, prostate, vagina)
  • Extremities

⭐ Sarcoma botryoides, an embryonal subtype, presents as a submucosal "bunch of grapes" (botryoid) mass, classically in the vagina or bladder.

Histopathology - The Cellular Suspects

• Rhabdomyoblast: The diagnostic cell. Can be round, or elongated (tadpole/strap cells) with eosinophilic, granular cytoplasm.
  • Cross-striations, resembling skeletal muscle, are pathognomonic but rarely seen.
• Major Subtypes:
  • Embryonal (ERMS): Most common (~60%). Spindle cells in a myxoid stroma. Includes the Sarcoma Botryoides variant ("bunch of grapes").
  • Alveolar (ARMS): Aggressive. Uniform, round cells lining fibrous septa, resembling lung alveoli.
• Immunohistochemistry (IHC) Markers: Myogenin (most specific), Desmin, and MyoD1.

⭐ Alveolar rhabdomyosarcoma is characterized by chromosomal translocations, typically t(2;13), creating a PAX3-FOXO1 fusion gene, which is linked to a poorer prognosis.

Clinical Features - Symptom Hotspots

• Site-dependent presentation. Mass effect is the primary driver of symptoms.
• Head & Neck (Most Common: ~40%)
  • Orbit: Proptosis (most common orbital malignancy in childhood).
  • Parameningeal (Nose, Sinuses, Middle Ear): Nasal/aural discharge, obstruction, cranial nerve palsies.
• Genitourinary (~25%)
  • Bladder/Prostate: Hematuria, urinary obstruction, pelvic mass.
  • Vagina/Uterus: 💡 Sarcoma botryoides - polypoid, grape-like mass protruding from the vagina.
  • Paratesticular: Painless scrotal mass.
• Extremities (~20%): Rapidly enlarging, firm, painless mass.

⭐ Sarcoma botryoides is the embryonal subtype of rhabdomyosarcoma, classically presenting as a "bunch of grapes" mass in the vagina or bladder of young girls.

Diagnosis & Staging - The Workup Blueprint

• Biopsy is Gold Standard: Incisional or excisional biopsy is mandatory for diagnosis.

  • HPE: Small, round, blue cells; may show tadpole or strap cells.
  • IHC Panel: Desmin, Myogenin, and MyoD1 are key markers.

• Staging Workup: A systematic search for local and distant disease.

⭐ The most critical factor for staging is the post-surgical Clinical Group (IRS), which assesses residual disease after the initial surgery.

Management - The Treatment Takedown

• Multimodal approach is key: Surgery + Chemotherapy ± Radiotherapy.
• Goal of Surgery: Wide local excision with negative margins, if feasible.
• Chemotherapy: Backbone of treatment. Standard regimen is VAC (Vincristine, Actinomycin D, Cyclophosphamide) or IVA (Ifosfamide, Vincristine, Actinomycin D).

⭐ Treatment is stratified by the Intergroup Rhabdomyosarcoma Study (IRS) post-surgical clinical group, which assesses the extent of residual disease after surgery.

High‑Yield Points - ⚡ Biggest Takeaways

• Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood, with a bimodal peak at 2-6 years and adolescence.
• The most common site is the head and neck (especially the orbit), followed by the genitourinary tract.
• Embryonal subtype is most frequent, has a better prognosis, and includes the sarcoma botryoides (grape-like) variant.
• Alveolar subtype has a worse prognosis, affects extremities, and is linked to t(2;13) translocation.
• Key diagnostic markers include Desmin and Myogenin.
• The characteristic cell is the rhabdomyoblast (tadpole or strap cell).